Baijin Life Science Holdings Limited (HKG:1466)

HKG:1466 Revenue

In the fiscal year ending March 31, 2026, Baijin Life Science Holdings had annual revenue of 89.30M HKD, down -34.12%. Baijin Life Science Holdings had revenue of 34.16M in the half year ending March 31, 2026, with 19.63% growth. That makes Baijin Life Science Holdings the 36,725th largest company in the world by revenue and 2,237th in Hong Kong.

• Revenue: 89.30M
• Revenue Growth: -34.12%
• P/S Ratio: 17.69
• Revenue / Employee: 1.06M
• Employees: 84
• Market Cap: 1.58B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Jewellery Business 63.57M 71.2%
• Skincare Business 25.73M 28.8%

By Geography

Chart

• Hong Kong 46.40M 52.0%
• The People's Republic of China (PRC) 25.73M 28.8%
• United States of America (USA) 16.85M 18.9%
• Others 329.00K 0.4%

Fiscal year ended Mar 31, 2026 See the full HKG:1466 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	89.30M	-46.25M	-34.12%
Mar 31, 2025	135.56M	81.88M	152.54%
Mar 31, 2024	53.68M	-33.20M	-38.22%
Mar 31, 2023	86.88M	24.23M	38.68%
Mar 31, 2022	62.65M	19.32M	44.60%

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 23, 2026

Data Sources Report a data error